SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical ...

Needham raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $34 from $29 and keeps a Buy rating on the shares. The firm views the ...

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). The company is looking to consolidate its older drug, Nuplazid, while boosting its ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, ...

Acadia Realty Trust’s fourth-quarter earnings remained relatively stagnant compared to previous times, but that hasn’t changed the company’s focus on expanding its street retail across the U.S. Acadia ...

Forbes contributors publish independent expert analyses and insights. We provide aggregated data on dividend stocks. Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar ...